Obesity Clinical Trial
— OLFO-FOODOfficial title:
OLFO-FOOD: OLFactory Odour Stimulation and FOOD Preferences
The aim of the present "OLFO-FOOD" clinical trial is to investigate, if olfactory stimulation impacts food choice, reference and calorie intake in humans with obesity assessed using a test buffet.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Age 18-60 years - Written informed consent - BMI =30 kg/m2 - Normosmia (as defined by Sniffin' Sticks Test) Exclusion Criteria: - Known allergy to olfactory stimulation substance, citrus fruits, citrus flavours, citrus food products - Lactose-intolerance, celiac disease or non-celiac wheat sensitivity - Diet other than omnivore or vegetarian - Eating disorder (now or in the past) - Dysphagia - Acute disease affecting food intake - Acute upper respiratory tract infection, acute or chronic sinusitis - Severe visual impairment (vision <10%) - Surgical intervention of the nasal cavity or the paranasal sinus - Current illicit drug abuse including daily marijuana and CBD (Cannabidiol) consumption (alcohol =2 drinks per day allowed) - Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease) - Type 1 and 2 diabetes mellitus - Treatment with insulin-sensitizing drugs within the last 3 months - Treatment with Glucagon-like Peptide 1 (GLP1)-analoga - History of neurodegenerative diseases, severe head trauma - Severe renal impairment (e.g. estimated glomerular filtration rate <30 ml/min/m2) - Known liver cirrhosis or other severe liver impairment - Use of any kind of decongestant more than twice a week - Uncontrolled dysthyroidism - Uncontrolled hypertension - Regular use of psychopharmaceutic drugs - Study participants aims to start a new diet or exercise program during the study - Bariatric surgery - Pregnancy/Lactation - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. - Participation in an interventional study within the last 3 months |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in calorie intake after olfactory stimulation | Olfactory stimulation compared to placebo in participants with obesity with a BMI =30 kg/m2 assessed by a test-buffet. | two time assessment at baseline and after 1 week | |
Secondary | Change in food preference after olfactory stimulation | Olfactory stimulation compared to placebo in participants with obesity with a BMI =30 kg/m2 assessed by a test-buffet.
Proportion of carbohydrates, fat and protein of the chosen food products (processed foods, warmed-up ready-to-eat meal, fresh fruits and vegetables) |
two time assessment at baseline and after 1 week | |
Secondary | Change of hunger assessed via VAS (Visual Analogue Scale) upon olfactory stimulation | Hunger will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change of appetite assessed via (Visual Analogue Scale) VAS upon olfactory stimulation | Appetite will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change of thirst assessed via (Visual Analogue Scale) VAS upon olfactory stimulation | Thirst will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change of nausea assessed via (Visual Analogue Scale) VAS upon olfactory stimulation | Nausea will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change of headache assessed via (Visual Analogue Scale) VAS upon olfactory stimulation | Headache will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change of mood assessed via (Visual Analogue Scale) VAS upon olfactory stimulation | Mood will be assessed via 10-point VAS Score (0= not at all, 10= maximum)) upon olfactory stimulation compared to placebo before and directly after olfactory stimulation, before and after exposure to a test-buffet. | up to eight time assessment from baseline till day 7 | |
Secondary | Change in plasma glucose Level (mmol/L) | Up to 5 blood samplings will be collected during each main visit, depending on the individual endpoint at the test-buffet: 4 blood samplings (60.8ml) if the participant eats the full 2 hours from the test-buffet, 5 samplings (76ml) if the participant stops eating from the test-buffet early.
Before olfactory stimulation (OS), (Baseline) After OS, before the test-buffet (TB0) After individual endpoint at the test-buffet (TBX) After 2 hours of test-buffet (TB2) After 2 hours of resting phase (TBR) |
up to 10 time assessment at visit one (Baseline, TB0, TBX, TB2, TBR) and after 1 week at visit 2 (Baseline TB0, TBX, TB2, TBR) | |
Secondary | Change in plasma insulin Level (pmol/L) | Up to 5 blood samplings will be collected during each main visit, depending on the individual endpoint at the test-buffet: 4 blood samplings (60.8ml) if the participant eats the full 2 hours from the test-buffet, 5 samplings (76ml) if the participant stops eating from the test-buffet early.
Before OS (Baseline) After OS, before the test-buffet (TB0) After individual endpoint at the test-buffet (TBX) After 2 hours of test-buffet (TB2) After 2 hours of resting phase (TBR) |
up to 10 time assessment at visit one (Baseline, TB0, TBX, TB2, TBR) and after 1 week at visit 2 (Baseline TB0, TBX, TB2, TBR) | |
Secondary | Change in serum cortisol Level (nmol/L) | Up to 5 blood samplings will be collected during each main visit, depending on the individual endpoint at the test-buffet: 4 blood samplings (60.8ml) if the participant eats the full 2 hours from the test-buffet, 5 samplings (76ml) if the participant stops eating from the test-buffet early.
Before OS (Baseline) After OS, before the test-buffet (TB0) After individual endpoint at the test-buffet (TBX) After 2 hours of test-buffet (TB2) After 2 hours of resting phase (TBR) |
up to 10 time assessment at visit one (Baseline, TB0, TBX, TB2, TBR) and after 1 week at visit 2 (Baseline TB0, TBX, TB2, TBR) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |